We could successfully translate our results into a clinical setting as high levels of Cdk5 were associated with a higher risk of relapse in early-stage MSS CRC patients that did not receive any treatment after primary tumor resection, especially in patients with KRAS-mutant tumors. This evidence concerns the gene KRAS and neoplasm.